Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>Design of dose-escalation phase. CRM, continuous reassessment model; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Kristoffer Staal Rohrberg (15009138) (author)
مؤلفون آخرون:	Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
منشور في:	2025
الموضوعات:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
حسب: Kristoffer Staal Rohrberg (15009138)
منشور في: (2025)

Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
حسب: Julio C. Chavez (15181310)
منشور في: (2025)

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
حسب: Julio C. Chavez (15181310)
منشور في: (2025)

Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
حسب: Julio C. Chavez (15181310)
منشور في: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
حسب: Niklas Klümper (15048887)
منشور في: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
حسب: Niklas Klümper (15048887)
منشور في: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
حسب: Ulka N. Vaishampayan (15051039)
منشور في: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
حسب: Ulka N. Vaishampayan (15051039)
منشور في: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
حسب: Ulka N. Vaishampayan (15051039)
منشور في: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
حسب: Ulka N. Vaishampayan (15051039)
منشور في: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
حسب: Noor Jailkhani (16015810)
منشور في: (2025)

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
حسب: Noor Jailkhani (16015810)
منشور في: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
حسب: Noor Jailkhani (16015810)
منشور في: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
حسب: John A. Ligon (15024477)
منشور في: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
حسب: Roger Li (17078665)
منشور في: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
حسب: Yan Zhou (15053225)
منشور في: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
حسب: Tom Wei-Wu Chen (15053003)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_mcm4s5u5lfqbb08ctlalfm17bu